Intellia Therapeutics Announces First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures subdued as investors weigh earnings, oil prices
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Intellia Therapeutics (NTLA) Misses Q1 EPS by 19c, Revenues Miss
May 7, 2020 7:44 AM EDTIntellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($0.63), $0.19 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $12.92 million versus the consensus estimate of $18.14 million.
At Intellia, our mission is to develop curative, CRISPR/Cas9-based treatments for severe diseases. I am... More
